Trial
NCT06015750
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Hypophosphatasia
Intervention
methotrexate
Why stopped
Sponsor decision following FDA release from the PMR.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-18